Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibikase Therapeutics, Inc.IKT · Entity 5838 | Director | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibikase Therapeutics, Inc.
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.91 · Expires 2036-06-26 | Direct | 155,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 155,000 · Balance 155,000 F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 20:05 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001193125-26-290476 · ownership.xml · derivative · entry 1 Canner David · CIK 0002041173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2036-06-26 F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 23:48 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 108,176 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000950170-25-093434 · ownership.xml · derivative · entry 1 Canner David · CIK 0002041173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,176 Underlying: Common Stock · 108,176 shares Expires 2032-06-30 F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:11 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 116,585 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0000950170-25-023583 · ownership.xml · derivative · entry 2 Canner David · CIK 0002041173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,585 Underlying: Common Stock · 116,585 shares Expires 2035-02-14 F2 · derivative.exercise_date: The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 01:11 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (Right to Buy) · Derivative | 22,640 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0000950170-25-023583 · ownership.xml · derivative · entry 1 Canner David · CIK 0002041173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,640 Underlying: Common Stock · 22,640 shares Expires 2035-02-14 F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 23:58 UTC | Inhibikase Therapeutics, Inc. IKT · Entity 5838 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0000950170-24-116787 · ownership.xml · derivative · entry 1 Canner David · CIK 0002041173 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-10-21 F1 · derivative.exercise_date: The option shares vest 50% on each of the first two anniversaries of October 21, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.